<PAGE>   1


                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION

                             WASHINGTON, D.C. 20549

                               -------------------

                                    FORM 10-Q

(Mark One)

[X]     Quarterly report pursuant to Section 13 or 15(d) of the Securities
        Exchange Act of 1934

              For the quarterly period ended September 30, 1999 or

[ ]     Transition report pursuant to Section 13 or 15(d) of the Securities
        Exchange Act of 1934

                 For the transition period from ______ to ______

                         Commission file number 0-18053

                                   LASERSCOPE
             (Exact name of Registrant as specified in its charter)

               CALIFORNIA                              77-0049527
        (State of Incorporation)          (I.R.S. Employer Identification No.)

               3052 ORCHARD DRIVE, SAN JOSE, CALIFORNIA 95134-2011
                    (Address of principal executive offices)

                  Registrant's telephone number: (408) 943-0636

Indicate by check mark whether the Registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the Registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.

                                Yes [X]  No [ ]

The number of shares of Registrant's common stock issued and outstanding as of
October 31, 1999 was 12,611,637.



<PAGE>   2

                                TABLE OF CONTENTS

<TABLE>
<CAPTION>
                                                                                   PAGE
                                                                                   ----
<S>                                                                                <C>
PART I.  FINANCIAL INFORMATION.....................................................   3
  Item 1.    Condensed Consolidated Balance Sheets.................................   3
             Condensed Consolidated Statements of Operations.......................   4
             Condensed Consolidated Statements of Cash Flows.......................   5
             Notes to Condensed Consolidated Financial Statements..................   6
  Item 2.    Management's Discussion and Analysis of
             Financial Condition and Results of Operations.........................   8
             Results of Operations.................................................   9
             Liquidity and Capital Resources.......................................  12
  Item 3.    Qualitative and Quantitative Disclosures About Market Risk............  14

PART II.  OTHER INFORMATION........................................................  15
  Item 1.    Legal Proceedings.....................................................  15
  Item 2.    Changes in Securities.................................................  15
  Item 3.    Defaults upon Senior Securities.......................................  15
  Item 4.    Submission of Matters to a Vote of Security Holders...................  15
  Item 5.    Other Items...........................................................  15
  Item 6.    Exhibits and Reports on Form 8-K......................................  15

SIGNATURES   ......................................................................  15
</TABLE>


                                        2
<PAGE>   3

PART I. FINANCIAL INFORMATION

ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS:

                                   LASERSCOPE
                      CONDENSED CONSOLIDATED BALANCE SHEETS
                                   (UNAUDITED)

<TABLE>
<CAPTION>
                                                           SEPTEMBER 30,    DECEMBER 31,
(thousands)                                                    1999             1998
----------------------------------------------------------------------------------------
<S>                                                          <C>              <C>
ASSETS

Current assets:
    Cash and cash equivalents                                $    887         $  1,456
    Accounts receivable, net                                    9,616           12,433
    Inventories                                                11,893           14,084
    Other current assets                                        1,635              867
                                                             --------         --------

           Total current assets                                24,031           28,840

Property and equipment, net                                     4,236            5,146
Developed technology and other intangibles, net                 2,736            2,089
Other assets                                                       --              518
                                                             --------         --------

           Total assets                                      $ 31,003         $ 36,593
                                                             ========         ========

LIABILITIES AND SHAREHOLDERS' EQUITY

Current liabilities:
    Accounts payable                                         $  4,679         $  5,360
    Accrued compensation                                        1,518            1,659
    Short-term bank loans                                       6,016            3,538
    Other current liabilities                                   3,477            4,561
                                                             --------         --------
        Total current liabilities                              15,690           15,118

Long-term liabilities:
    Obligations under capital leases                              612              786
    Mortgages and other long term loans                         1,693            1,693
                                                             --------         --------
        Total long-term liabilities:                            2,305            2,479

Commitments and contingencies

Minority interest                                                 194              325

Shareholders' equity:
        Common stock                                           51,268           51,268
        Accumulated deficit                                   (37,526)         (31,627)
        Accumulated other comprehensive income                   (726)            (599)
        Notes receivable from shareholders                       (202)            (371)
                                                             --------         --------

           Total shareholders' equity                          12,814           18,671
                                                             --------         --------

           Total liabilities and shareholders' equity        $ 31,003         $ 36,593
                                                             ========         ========
</TABLE>


See notes to condensed consolidated financial statements


                                       3
<PAGE>   4

                                   LASERSCOPE
                 CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
                                   (UNAUDITED)

<TABLE>
<CAPTION>
                                                    THREE MONTHS ENDED                 NINE MONTHS ENDED
                                                        SEPTEMBER 30,                    SEPTEMBER 30,
(thousands except per share amounts)               1999             1998             1999             1998
------------------------------------------------------------------------------------------------------------
<S>                                              <C>              <C>              <C>              <C>
Net revenues ..................................  $  9,892         $ 12,779         $ 31,323         $ 39,503
Cost of sales .................................     5,410            6,976           18,322           21,618
                                                 --------         --------         --------         --------

Gross margin ..................................     4,482            5,803           13,001           17,885

Operating expenses:
    Research and development ..................       989            1,179            3,553            3,862
    Selling, general and administrative .......     4,441            4,813           14,127           15,881
                                                 --------         --------         --------         --------

                                                    5,430            5,992           17,680           19,743

Operating loss ................................      (948)            (189)          (4,679)          (1,858)
Interest income (expense) and other, net ......      (345)            (138)          (1,027)            (454)
                                                 --------         --------         --------         --------

Loss before income taxes
    and minority interest .....................    (1,293)            (327)          (5,706)          (2,312)
Provision for income taxes ....................        13              178              141              311
                                                 --------         --------         --------         --------

Loss before minority interest .................    (1,306)            (505)          (5,847)          (2,623)
Minority interest .............................         2              232               52              321
                                                 --------         --------         --------         --------

Net loss ......................................  $ (1,308)        $   (737)        $ (5,899)        $ (2,944)
                                                 ========         ========         ========         ========

Basic and diluted net loss per share ..........  $  (0.10)        $  (0.06)        $  (0.47)        $  (0.24)
                                                 ========         ========         ========         ========

Shares used in basic and
   diluted per share calculations .............    12,550           12,469           12,564           12,405
                                                 ========         ========         ========         ========
</TABLE>



See notes to condensed consolidated financial statements



                                       4
<PAGE>   5

                                   LASERSCOPE
                 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
                                   (UNAUDITED)

<TABLE>
<CAPTION>
                                                                         NINE MONTHS ENDED
                                                                           SEPTEMBER 30,
(thousands)                                                             1999            1998
---------------------------------------------------------------------------------------------
<S>                                                                   <C>             <C>
CASH FLOWS FROM OPERATING ACTIVITIES
    Net loss                                                          $(5,899)        $(2,944)
    Adjustments to reconcile net loss to
      cash used by operating activities:
        Depreciation and amortization                                   2,362           2,261
        Excess Inventory charge                                           750              --
        Compensation relating to repayment of shareholder note            169              --
        Increase (decrease) from changes in:
           Accounts receivable                                          2,817             506
           Inventories                                                  1,441             145
           Other current assets                                          (768)             45
           Accounts payable                                              (681)           (253)
           Accrued compensation                                          (141)            308
           Other current liabilities                                     (999)         (1,192)
           Minority interest                                               52             325
                                                                      -------         -------

           Cash used by operating activities                             (897)           (799)
                                                                      -------         -------

CASH FLOWS FROM INVESTING ACTIVITIES:
    Capital expenditures                                                 (474)           (908)
    NWL acquisition                                                    (1,278)             --
    Other                                                                (127)            146
                                                                      -------         -------

Cash used by investing activities                                      (1,879)           (762)
                                                                      -------         -------

CASH USED BY FINANCING ACTIVITIES:
    Payments on obligations under capital leases                         (271)           (143)
    Proceeds from the sale of common stock under stock plans               --             189
    Proceeds from bank loans                                            3,621           1,603
    Repayment of bank loans                                            (1,143)         (1,221)
                                                                      -------         -------

Cash provided by financing activities                                   2,207             428
                                                                      -------         -------

Decrease in cash and cash equivalents                                    (569)         (1,133)
Cash and cash equivalents, beginning of period                          1,456           2,465
                                                                      -------         -------

Cash and cash equivalents, end of period                              $   887         $ 1,332
                                                                      =======         =======

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
        Cash paid during the period for:
           Interest                                                   $   378         $   308
           Income taxes                                               $    15         $    14
        Non-cash financing activities:
           Equipment leases                                           $    12         $   680
</TABLE>



See notes to condensed consolidated financial statements



                                       5
<PAGE>   6

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS:

1.      The accompanying condensed consolidated financial statements include
        Laserscope (the "Company") and its wholly and majority-owned
        subsidiaries. All intercompany transactions and balances have been
        eliminated. While the financial information in this report is unaudited,
        in the opinion of management, all adjustments (which include only normal
        recurring adjustments) necessary to present fairly the financial
        position and results of operations as of and for the periods indicated
        have been recorded. It is suggested that these consolidated financial
        statements be read in conjunction with the consolidated financial
        statements and the notes thereto for the year ended December 31, 1998
        included in the Company's annual report on Form 10-K for the year ended
        December 31, 1998. The results of operations for the three and nine
        month periods ended September 30, 1999 are not necessarily indicative of
        the results expected for the full year.

2.      Inventory was comprised of the following (in thousands):

<TABLE>
<CAPTION>
                                                SEPTEMBER 30,   DECEMBER 31,
                                                   1999           1998
                                               -------------   ------------
<S>                                            <C>             <C>
        Sub-assemblies and purchased parts        $ 8,588        $ 9,371
        Finished goods                              3,305          4,713
                                                  -------        -------
                                                  $11,893        $14,084
                                                  =======        =======
</TABLE>

3.      Basic net income (loss) per share is calculated using the weighted
        average of common stock outstanding. Diluted net income per share is
        calculated using the weighted average of common stock outstanding plus
        dilutive common equivalent shares from stock options. Options to
        purchase approximately 3,609,000 and 2,588,000 shares of common stock
        were outstanding at September 30, 1999 and 1998, respectively. Options
        were not included in the computation of diluted earnings (loss) per
        share because the Company reported losses for the periods that ended at
        these dates and, therefore, the effect would be anti-dilutive.

4.      The Company considers cash equivalents to be short-term financial
        instruments that are readily convertible to cash, subject to no more
        than insignificant interest rate risk and that have original maturities
        of three months or less.

        At September 30, 1999 and December 31, 1998, the Company's cash
        equivalents were in the form of institutional money market accounts and
        totaled $0.4 million and $0.4 million, respectively. At September 30,
        1999 and December 31, 1998, the Company had no investments in debt or
        equity securities.

5.      During the year ended December 31, 1998, the Company adopted Statement
        of Financial Accounting Standards No. 130, "Reporting Comprehensive
        Income" (SFAS 130). SFAS 130 requires translation adjustments, which
        prior to adoption were reported in shareholders' equity, to be included
        in comprehensive income (loss). The total comprehensive loss during the
        quarters and nine month periods ended September 30, 1999 and 1998
        consisted of (in thousands):



                                       6
<PAGE>   7

<TABLE>
<CAPTION>
                                          THREE MONTHS ENDED               NINE MONTHS ENDED
                                              SEPTEMBER 30,                   SEPTEMBER 30,
                                         --------------------            ---------------------
                                         1999            1998            1999            1998
        --------------------------------------------------------------------------------------
<S>                                    <C>             <C>             <C>             <C>
        Net loss                       $(1,308)        $  (737)        $(5,899)        $(2,944)
        Translation adjustments           (195)            236            (127)            212
                                       -------         -------         -------         -------
        Comprehensive loss             $(1,503)        $  (501)        $(6,026)        $(2,732)
                                       =======         =======         =======         =======
</TABLE>

6.      During the year ended December 31, 1998, Laserscope adopted Statement of
        Financial Accounting Standards No. 131, "Disclosures about Segments of
        an Enterprise and Related Information" (SFAS 131). SFAS 131 changed the
        way companies report selected segment information in annual financial
        statements and requires those companies to report selected segment
        information in interim financial reports to shareholders. During all
        periods presented, the Company conducted its business predominantly
        within one industry segment: the medical systems business.

7.      In January 1999, pursuant to an agreement between Laserscope and the
        minority interest owners of NWL Laser-Technologie GmbH ("NWL"), the
        Company paid approximately $0.8 million in cash, and an additional $0.5
        million in April 1999, to acquire an additional 27% interest in NWL.
        These purchases bring Laserscope's ownership interest in NWL to 79%. The
        approximate purchase price allocation for the transaction is $1.1
        million for intangible assets (including developed technology,
        distribution and workforce) and $0.2 million for additional interest in
        tangible assets. The Company expects to pay an additional $1.0 million
        in January 2001 for the remaining interest in NWL.



                                       7
<PAGE>   8

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
        OF OPERATIONS:

Except for the historical information contained in this Quarterly Report on Form
10-Q, the matters discussed herein are forward-looking statements made pursuant
to the safe harbor provisions of the Private Securities Litigation Reform Act of
1995. Investors are cautioned that all forward-looking statements are subject to
certain risks and uncertainties that could cause the actual results to differ
materially from those projected. Factors that could cause actual results to
differ materially include, but are not limited to, the risks associated with the
acquisition of NWL Laser-Technologie, GmbH ("NWL"), including the integration of
the operations and assets acquired and the assumption of the liabilities assumed
by Laserscope, the timing of orders and shipments, the Company's ability to
balance its inventory and production schedules, the timely development,
clearance by the F.D.A. and other regulatory agencies and market acceptance of
new products and surgical/therapeutic procedures, the impact of competitive
products and pricing, Laserscope's ability to raise capital on terms acceptable
to the Company, or at all, the Company's ability to expand further into
international markets, and public policy relating to health care reform in the
United States and other countries.

Laserscope intends to continue expansion of its operations outside of the United
States and to enter additional international markets, requiring significant
management attention and financial resources and further subjecting the Company
to the risks of operating internationally. These risks include unexpected
changes in regulatory requirements, delays resulting from difficulty in
obtaining export licenses for certain technology, customs, tariffs and other
barriers and restrictions, and the burdens of complying with a variety of
foreign laws. The Company is also subject to general geopolitical risks in
connection with its international operations, such as political and economic
instability and changes in diplomatic and trade relationships. The Company
cannot predict whether quotas, duties, taxes or other charges or restrictions
will be imposed by the United States, Japan, countries in the European Union or
other countries upon the import or export of Laserscope's products in the
future, or what effect any such actions would have on its business, financial
condition or results of operations. In addition, fluctuations in currency
exchange rates may negatively affect the Company's ability to compete in terms
of price against products denominated in local currencies. There can be no
assurance that regulatory, geopolitical and other factors will not adversely
affect the Laserscope's operations in the future or require Laserscope to modify
its current business practices.

Many currently installed computer systems and software products are coded to
accept only two digit entries in the date field. Beginning in the year 2000,
these date fields need to accept four digit entries to distinguish 21st century
dates from 20th century dates. As a result, in approximately two months,
computer systems and/or software used by many companies may need to be upgraded
to comply with such "Year 2000" requirements. Significant uncertainty exists
concerning the potential effects associated with any noncompliance. Any Year
2000 compliance problem encountered by Laserscope, its suppliers, its service
providers or its customers could have a material adverse effect on the Company's
financial condition and operating results.

Other risks are detailed from time to time in Laserscope's press releases and
other public disclosure filings with the U.S. Securities and Exchange Commission
(SEC), copies of which are available upon request from the Company. The
forward-looking statements included



                                       8
<PAGE>   9

herein speak only as of the date hereof. Laserscope assumes no obligation to
update any forward-looking statements included herein.

RESULTS OF OPERATIONS:

The following discussion should be read in conjunction with the unaudited
consolidated financial statements and notes thereto included in Part I -- Item 1
of this Quarterly Report and the audited financial statements and notes thereto
and Management's Discussion and Analysis of Financial Condition and Results of
Operations for the year ended December 31, 1998 contained in the Company's
Annual Report on Form 10-K.

The following table contains selected income statement information, which serves
as the basis of the discussion of the Company's results of operations for the
quarter and nine months ended September, 1999 (in thousands except for
percentages):


<TABLE>
<CAPTION>
                                     THREE MONTHS ENDED                            NINE MONTHS ENDED
                              SEPT. 30, 1999     SEPT. 30, 1998       %     SEPT. 30,1999         SEPT. 30, 1998       %
                                AMOUNT %(a)       AMOUNT %(a)      CHANGE    AMOUNT %(a)           AMOUNT %(a)       CHANGE
                             --------------    ----------------    -------  --------------      -------------------  ------
<S>                          <C>        <C>   <C>          <C>      <C>     <C>          <C>    <C>           <C>     <C>
Revenues from sales of:
  Lasers                     $5,381     54%   $ 6,955      55%      (23)%   $17,756      57%    $ 20,891      53%     (15)%
  Ascent medical systems          -      -      1,329      10%     (100)%         -       -        4,382      11%    (100)%
  Instruments & supplies      2,881     29%     2,916      23%       (1)%     8,808      28%       9,106      23%      (3)%
  Service                     1,630     17%     1,579      12%        3 %     4,759      15%       5,124      13%      (7)%
                             ------    ---    -------    ----      ----     -------    ----     --------     ---     ----
  Total net revenues         $9,892    100%   $12,779     100%      (23)%   $31,323     100%    $ 39,503     100%     (21)%

Gross margin                 $4,482     45%   $ 5,803      45%      (23)%   $13,001      42%    $ 17,885      45%     (27)%

Research & development       $  989     10%   $ 1,179       9%      (16)%   $ 3,553      11%    $  3,862      10%      (8)%

Selling, general & admin     $4,441     45%   $ 4,813      38%       (8)%   $14,127      45%    $ 15,881      40%     (11)%

</TABLE>
(a)     expressed as a percentage of total net revenues.

Net revenues decreased during the three and nine months ended September 30, 1999
relative to the corresponding periods of 1998 as a combined result of lower
shipments of lasers, instrumentation and supplies. Sales of services were higher
during the three months ended September 30, 1999 and lower during the nine
months ended September 30, 1999 compared to the corresponding periods in 1998.
In addition, due to the sale of the Ascent Medical System ("AMS") assets and
liabilities in November 1998, Laserscope had no sales of AMS products in 1999
while sales of these products were $1.3 million and $4.4 million in the three
and nine months ended September 30, 1998, respectively.

Revenues from the sales of laser systems decreased during the quarter and
nine-month periods ended September 30, 1999 relative to the same periods in
1998. This was due to a combination of lower unit shipments and lower average
unit prices during the quarter and lower unit shipments and higher average unit
prices during the nine months period. The lower unit shipments are the result of
decreased shipments of the Company's Surgical Laser Systems, principally in the
United States and the Pacific Rim. The lower average unit prices during the
three months ended September 30, 1999 are due primarily to a higher mix of
office lasers world-wide. The higher average unit prices during the nine months
ended September 30, 1999 reflect the higher mix of PDT units sold in the United
States and lower shipments to customers in Asia during the first six months of
1999. In spite of higher laser system unit prices in the United States during
the nine months of 1999 compared to the first nine months of 1998, the Company
expects its future revenue mix trends in the U.S. market to shift toward


                                        9
<PAGE>   10


lower-priced lasers. In addition, Laserscope believes that economic conditions
in the Pacific Rim region will continue to affect its revenues negatively.

Revenues from the sales of instrumentation and disposable supplies during the
quarter and nine months ended September 30, 1999 decreased compared to the
corresponding periods in 1998. The decrease is due to the combination of lower
shipments of disposable supplies and decreased shipments of scanning devices
sold as accessories to the Aura office laser system. The Company believes that
trends in sales of laser equipment in the United States towards office lasers
for aesthetic procedures and away from lasers to be used in the hospital for
non-aesthetic procedures have resulted in decreased sales of disposable
supplies. Office lasers used in aesthetic procedures, although often times
carrying accompanying one-time sales of instrumentation, generally do not create
a stream of sales of disposable supplies. The Company expects revenues from the
sales of instrumentation and disposable supplies will depend on Laserscope's
ability to increase its installed base of systems, and to promote and develop
surgical procedures that use these products.

Laserscope's service revenues increased during the three-month period and
decreased during the nine-month period ended September 30, 1999 compared to the
same periods in 1998. The increase during the three-month period is primarily
due to increased non-domestic revenues. The decrease during the nine-month
period is principally attributable to lower domestic revenues resulting from
reduced service contract revenues from hospitals, partially offset by increased
non-domestic service revenues. The Company believes that future revenues depend
on increases to the installed base of lasers as well as the acceptance of its
service contracts by its customers.

The Company believes that acceptance of lasers in aesthetic surgery,
dermatology, urology and ear, nose and throat surgery will continue to be
important to its business. In addition, the Company expects that the adoption of
photodynamic therapy by medical practitioners will be important to its business.
The Company continues to invest in developing new instrumentation for emerging
surgical applications and in educating surgeons in the United States and
internationally to encourage the adoption of such new applications. Penetration
of the international market is generally increasing, and the Company continues
to view expansion of international sales as important to its success. During the
first nine months of 1999, international revenues accounted for 46% of total net
revenues, compared to 39% of total net revenues during the first nine months of
1998. The increase as a percentage of total net revenues is due principally to
the discontinuance of sales of AMS products which were sold by the Company only
in the United States, and, to a lesser extent, higher international revenues.


Gross margin as a percentage of revenues remained constant during the quarter
ended and decreased during the and nine months ended September 30, 1999 relative
to the corresponding periods of 1998. The decline is due principally to lower
production levels without corresponding reductions in fixed manufacturing costs.
The decline in production levels is the combined result of lower shipment levels
in the 1999 periods compared to 1998 periods as well as the Company's efforts to
reduce inventory levels. In addition, Laserscope recorded a $0.8 million charge
during the period ended June 30, 1999, to provide for inventory the Company
considered potentially obsolete. The Company expects that gross margin as a
percentage of revenues for the remainder of 1999 will vary from quarter to
quarter as it continues to balance production volumes and inventory levels with
product demand and as product and distribution mix varies.

                                       10
<PAGE>   11


Research and development expenses are the result of activities related to the
development of new laser, instrumentation and disposable products and the
enhancement of the Company's existing products. The decreases in research and
development spending during the nine month period ended September 30, 1999
relative to the corresponding period in 1998 is due to decreased laser product
development activity in the United States. The Company expects amounts spent in
research and development to remain at similar levels during the remainder of
1999.

Selling, general and administrative expenses decreased during the quarter and
nine-month periods ended September 30, 1999. This is due to a number of factors.
As a result of the sale of AMS assets and liabilities in November 1998,
Laserscope reduced expenses relating to the sales and marketing of AMS products.
In addition, the Company has generally reduced selling, general and
administrative expenses under expense control measures instituted during the
latter part of 1998. Partially offsetting these reductions is approximately $1.0
million in charges recorded by Laserscope relating to severance arrangements
with employees that were terminated in reductions in force during 1999.


Laserscope expects amounts spent in selling, general and administrative expenses
during the final quarter of 1999 to be lower than amounts spent during the first
three quarters of 1999. The expected reductions are due to continued expense
reduction programs instituted by the Company late in the quarter ended June 30,
1999.

                                       11
<PAGE>   12


LIQUIDITY AND CAPITAL RESOURCES:

The following table contains selected balance sheet information that serves as
the basis of the discussion of the Company's liquidity and capital resources at
September 30, 1999 and for the nine months then ended (in thousands):

<TABLE>
<CAPTION>
                                              SEPTEMBER 30,        DECEMBER 31,
                                                  1999                 1998
                                              -------------        ------------
<S>                                           <C>                  <C>
Cash and cash equivalents                          $   887          $    1,456
Total assets                                       $31,003          $   36,593
Net working capital                                $ 8,341          $   13,722

</TABLE>


The net decrease in cash and cash equivalents during the nine month period was
due primarily to the combination of net proceeds from bank borrowings of $2.5
million, $1.3 million paid to increase Laserscope's interest in NWL, cash used
by operating activities of $0.9 million and capital expenditures of $0.5
million.

Cash provided by operating activities was the combined result of a net loss of
$5.9 million, a decrease in other current liabilities of $1.0 million, an
increase to other current assets of $0.8 million, a decrease in accounts payable
of $0.7 million and a decrease to accrued compensation of $0.1 million.
Offsetting these uses were a reduction in accounts receivable of $2.8 million,
depreciation and amortization of $2.4 million, a reduction in inventory of $1.4
million, an excess inventory charge of $0.8 million and a decrease in
shareholder notes receivable of $0.2 million.

Cash used by investing activities primarily consisted of capital expenditures of
$0.5 million and increased investment in NWL of $1.3 million.

Cash provided by financing activities primarily consisted of net increases in
bank loans of $2.5 million.

At September 30, 1999, Laserscope had approximately $4.4 million outstanding
under its bank credit line. The losses reported by the Company during the
quarters ended June 30, 1999 and September 30, 1999 violated the profitability
and minimum net worth covenants of the loan agreement. On October 1, 1999,
Laserscope moved to a $6.0 million asset-based borrowing arrangement with the
same bank with collateral values based principally on domestic accounts
receivable. The arrangement, which expires in September 2000, allows for an
over-advance relative to the collateral of $1.9 million until December 31, 1999,
then $1.0 million until March 31, 2000 at which time further over-advances will
no longer be allowed. At October 1, 1999, the Company had approximately $4.4
million in collateral available against the $4.4 million outstanding.

In addition, NWL has in place various bank lines totaling approximately $2.0
million that expire in 1999 and 2000 under which $1.0 million in borrowings were
outstanding at September 30, 1999.

The Company anticipates that future changes in cash and working capital will be
dependent on a number of factors including management's ability to manage
effectively non-cash assets such as inventory and accounts receivable. The
Company competes in a competitive industry where technological changes and
acceptance of new and alternative procedures by its customers is rapid.
Management's ability to anticipate and adapt to these changes will significantly
affect the Company's investment in inventory and the potential for inventory


                                       12
<PAGE>   13

valuation adjustments. In addition, the level of profitability of the Company
will have a significant impact on cash resources.

From time to time, the Company may also consider the acquisition of, or evaluate
investments in, certain products and businesses complementary to the Company's
business. Any such acquisition or investment may require additional capital
resources. The Company has historically financed acquisitions using its existing
cash resources. While the Company believes its remaining cash resources will be
sufficient to fund its operating needs for the next twelve months, additional
financing either through its bank lines of credit or otherwise will be required
for the Company's currently envisioned long term needs. There can be no
assurance that such additional financing will be available on terms acceptable
to the Company, or at all.

YEAR 2000

As described earlier, the year 2000 computer issue creates a risk for
Laserscope. If computer systems do not correctly recognize date information when
the year changes to 2000, there could be a material adverse effect on the
Company's operations. The risk for the Company exists in four areas: (i)
Information systems and equipment used by the Company to operate its business;
(ii) systems used by the Company's suppliers; (iii) the products sold by the
Company; and (iv) the potential for reduced spending by customers for
Laserscope's products and services as a result of significant spending on year
2000 issues and related adverse effects of such issues on the customer's
business.

Laserscope has completed its upgrade of the business critical internal
information systems and equipment that the Company had identified to be year
2000 non-compliant. At this time, Laserscope has developed contingency plans,
consistent with its other disaster recovery plans, to address the potential of
unidentified year 2000 non-compliance. For the year 2000 non-compliance issues
identified to date, the cost of upgrade or replacement has been less than
$200,000 through September 30, 1999. Laserscope does not expect any remaining
costs of year 2000-related upgrades or replacements to affect materially its
operating results. The Company intends to fund any such compliance efforts
through working capital generated by operations. If significant new
non-compliance issues are identified, the Company's results of operations or
financial condition could be adversely affected. However, the Company believes
that it has completed its year 2000 compliance review and necessary system
modifications and does not anticipate adverse consequences.

Laserscope has also contacted its critical suppliers to determine whether such
suppliers' operations and the products and services they provide to the Company
are year 2000 compliant, and has evaluated the responses. At present, Laserscope
is satisfied with the responses from these critical suppliers. Where practical,
the Company will attempt to mitigate its risks with respect to the failure of
its suppliers to be year 2000 ready. In the event that suppliers are not year
2000 compliant, the Company may need to seek alternative sources. Any such
failures by critical suppliers could have a material adverse effect on the
Company's results of operations or financial condition.

Laserscope believes that the majority of the products it sells are year 2000
compliant in all material respects; however, because all customer situations
cannot be anticipated, the Company may see an increase in warranty and other
claims as a result of the year 2000 transition. While litigation regarding year
2000 compliance issues is expected to escalate, the Company does not believe
that the effect of customer claims is reasonably likely to materially affect the
Company's results of operations or financial condition.


                                       13
<PAGE>   14

Year 2000 compliance is an issue for virtually all businesses whose systems and
applications may require significant hardware and software upgrades or
modifications. Companies owning and operating such systems may plan to devote a
substantial portion of their information systems' spending to fund such upgrades
and modifications and divert spending away from the purchase of the Company's
products and services. Such changes in customers' spending patterns could have
an adverse effect on the Company's sales, but the effect on operating results
and financial condition is not known at this time.


ITEM 3. QUALITATIVE AND QUANTITATIVE DISCLOSURES ABOUT MARKET RISK

The Company is exposed to a variety of risks, including changes in interest
rates affecting the return on its investments, outstanding debt balances and
foreign currency fluctuations. In the normal course of business, the Company
employs established policies and procedures to manage its exposure to
fluctuations in interest rates and foreign currency values.

INTEREST RATE RISK

The Company's exposure to market rate risk for changes in interest rates relate
primarily to the Company's investment and debt portfolios. Laserscope has not
used derivative financial instruments in its investment or debt portfolios. The
Company invests its excess cash in money market funds and commercial paper. The
Company's debt financing consists mainly of bank loans requiring either fixed or
variable rate interest payments. Investments in and borrowings under both
fixed-rate and floating-rate interest-earning instruments carry a degree of
interest rate risk. On the investment side, fixed-rate securities may have their
fair market value adversely affected due to a rise in interest rates, while
floating-rate securities may produce less income than expected if interest rates
fall. In addition, Laserscope's future investment income may fall short of
securities analyst expectations due to changes in interest rates or the Company
may suffer losses in principal if forced to sell securities which have declined
in market value due to changes in interest rates. On the debt side, borrowings
that require fixed-rate interest payments require greater than current market
rate interest payments if interest rates fall, while floating rate borrowings
may require greater interest payments if interest rates rise. Additionally, the
Company's future interest expense may be greater than expected due to changes in
interest rates.

FOREIGN CURRENCY RISK

International revenues were 46% of total revenues in the nine months ended
September 30, 1999, compared to 39% of total revenues during the comparable
period in 1998. International sales are made through international distributors
and wholly- and majority-owned subsidiaries with payments to Laserscope
typically denominated in the local currencies of the United Kingdom, France and
Germany, and in U.S. dollars in the rest of the world. The Company's
international business is subject to risks typical of an international business,
including, but not limited to, differing economic conditions, changes in
political climate, differing tax structures, other regulations and restrictions,
and foreign exchange rate volatility. Accordingly, the Company's future results
could be materially adversely affected by changes in these or other factors. The
effect of foreign exchange rate fluctuations on the Company in the quarters and
nine month periods ended September 30, 1999 and 1998 were not material, and the
Company does not engage in hedging transactions for speculative or trading
purposes.

                                       14
<PAGE>   15



PART II.       OTHER INFORMATION

ITEM 1.        LEGAL PROCEEDINGS

               The Company is a party to a number of legal proceedings arising
               in the ordinary course of business. While it is not feasible to
               predict or determine the outcome of the actions brought against
               it, the Company believes that the ultimate resolution of these
               claims will not ultimately have a material adverse effect on its
               financial position or results of operations.

ITEM 2.        CHANGES IN SECURITIES
               Not applicable.

ITEM 3.        DEFAULTS UPON SENIOR SECURITIES
               Not applicable.

ITEM 4.        SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
               Not applicable.

ITEM 5.        OTHER INFORMATION
               None

ITEM 6.        EXHIBITS AND REPORTS ON FORM 8-K

        (a)    Exhibits:  None
        (b)    Reports on Form 8-K:  None

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.

                                  LASERSCOPE
                                  Registrant

                                  /s/  Dennis LaLumandiere
                                  ---------------------------------------------
                                  Dennis LaLumandiere
                                  Vice President of Finance
                                    and Chief Financial Officer
                                    (Principal Financial and Accounting Officer)
Date:  November 12, 1999


                                       15
<PAGE>   16

                                 EXHIBIT INDEX

Exhibit#            Description

 27.1               Financial Data Schedule